Bellus Health

About Us

Our Company

Our Company

BELLUS Health (Nasdaq:BLU, TSX:BLU) is a clinical stage biotechnology company developing novel therapeutics for the treatment of refractory chronic cough and other disorders associated with hypersensitization. The Company’s lead product candidate, BLU-5937, is a highly selective P2X3 antagonist being developed for the treatment of refractory chronic cough. The Company has initiated the CALM Phase 3 program, which consists of two pivotal trials CALM-1 and CALM-2.

BELLUS is evaluating potential opportunities to study BLU-5937 for the treatment of other cough disorders and hypersensitization disorders where hypersensitivity plays a key role.

We invite you to visit our investors’ relations page, including our Annual Information Form, to obtain more information about BELLUS Health.

Management Team

Roberto Bellini

Roberto Bellini

President and Chief
Executive Officer

Read More

Dr. Catherine Bonuccelli

Chief Medical Officer

Read More
Ramzi Benamar

Ramzi Benamar

Chief Financial Officer

Read More
Dr. Denis Garceau

Dr. Denis Garceau

Chief Scientific Officer

Read More

Dr. Andreas Orfanos

Chief Operating Officer

Read More

François Desjardins

Senior Vice President,
Finance

Read More
Tony Matzouranis

Tony Matzouranis

Senior Vice President,
Business Development

Read More

Board of Directors

Roberto Bellini

Read More

Dr. Francesco Bellini

Chair

Read More

Dr. Youssef L. Bennani

Read More

Franklin M. Berger

Read More

Dr. Clarissa Desjardins

Read More

Pierre Larochelle

Read More

Dr. William Mezzanotte

Read More

Joseph Rus

Read More

Chronic Cough
Clinical Advisory Board

Dr. Jacky Smith, MB,
ChB, FRCP, PhD

Chair

Read More

Dr. Alan Goldsobel, MD

Read More

Dr. James Hull, BSc, MBBS,
FRCP, PhD, FACSM

Read More

Dr. Lorcan McGarvey,
MD, FRCP

Read More

Dr. Alyn Morice, MD

Read More

Dr. Mandel Sher, MD

Read More